About This Guide

This guide provides supplementary clinical information for the Tedizolid Dose Calculator. It details the standard dosing regimen for tedizolid, explains the clinical parameters used, and outlines key safety considerations based on official prescribing information. The content is intended for healthcare professionals and should not replace clinical judgment.

Understanding the Outputs

The calculator determines the standard therapeutic dose for adults and provides essential advisories. The key outputs are:

• Recommended Dose: The specific milligram strength for administration (e.g., 200 mg).
• Route & Frequency: Indicates that the dose can be given intravenously (IV) or orally (PO) once daily.
• Treatment Duration: A fixed 6-day course for its approved indication.
• Clinical Advisories: Notes regarding dosage adjustments for special populations, such as those with renal or hepatic impairment.
• Calculated CrCl (Optional): If the calculation option is chosen, it displays the estimated creatinine clearance using the Cockcroft-Gault equation.

How to Use the Calculator

To use the tool effectively, input the following patient data:

• Age: Patient's age in years. The tool is intended for adults (≥18 years).
• Weight: Required for the optional CrCl calculation. Can be entered in kilograms (kg) or pounds (lbs).
• Sex: A required parameter for the Cockcroft-Gault formula.
• Indication: Tedizolid is approved for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
• Renal Function: You can either enter a known creatinine clearance (CrCl) or eGFR value, or have the tool calculate it by providing the patient's serum creatinine (SCr).
• Hepatic Function: Specify the patient's liver function status (Normal, or Child-Pugh Class A, B, or C).

Dosing Overview

The standard dosing for tedizolid phosphate in adult patients is straightforward and does not typically require adjustment.

Standard Adult Dose for ABSSSI

200 mg Once Daily 6-Day Course

This regimen applies to both intravenous (IV) and oral (PO) administration.

Special Populations

Switching Between IV and Oral Therapy

Tedizolid phosphate has excellent oral bioavailability (approximately 91%). Patients who begin treatment with the intravenous formulation may be switched to the oral formulation when clinically appropriate. No dose adjustment is required when switching from IV to PO administration.

Missed Dose Protocol

If a dose of tedizolid is missed, the patient should take it as soon as they remember. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should resume their regular dosing schedule. It is important not to take two doses at once to make up for a missed dose.

Safety Alerts

• Myelosuppression: Anemia, leukopenia, neutropenia, and thrombocytopenia have been observed. Monitor complete blood counts weekly in patients receiving tedizolid, particularly those with pre-existing myelosuppression or on concomitant medications that may cause it.
• Serotonergic Drug Interactions: Tedizolid is a reversible, nonselective monoamine oxidase (MAO) inhibitor. Co-administration with certain serotonergic agents (e.g., SSRIs, SNRIs, TCAs, triptans) should be avoided or managed with careful monitoring for serotonin syndrome.
• Clostridioides difficile-Associated Diarrhea (CDAD): As with other antibacterial agents, CDAD has been reported and may range in severity from mild diarrhea to fatal colitis.

Frequently Asked Questions (FAQ)

1. Does the calculator provide dose adjustments for renal impairment?

No, because tedizolid does not require dose adjustments for any degree of renal impairment, including patients on hemodialysis. The calculator confirms this standard approach.

2. Why does the tool ask for age, weight, and sex?

These parameters are used only if you select the "Calculate CrCl" option. They are inputs for the Cockcroft-Gault formula to estimate renal function.

3. Can this calculator be used for pediatric patients?

No. The safety and effectiveness of tedizolid in patients under 18 years of age have not been established.

4. What formula is used to calculate creatinine clearance?

The tool uses the Cockcroft-Gault equation to estimate CrCl when serum creatinine is provided.

5. Is a dose adjustment needed for patients with severe liver disease (Child-Pugh C)?

No, dose adjustment is not required for patients with any degree of hepatic impairment.

6. What is the standard duration of therapy for tedizolid?

The recommended duration for ABSSSI is a fixed 6-day course.

7. Is a loading dose required for tedizolid?

No, a loading dose is not part of the recommended dosing regimen.

8. Does obesity affect the standard 200 mg dose?

Clinical trials did not show a need for dose adjustment based on weight or body mass index (BMI). The standard 200 mg dose is recommended for all adult patients regardless of weight.

References

• SIVEXTRO® (tedizolid phosphate) Prescribing Information. U.S. Food and Drug Administration. Revised: 01/2021.
• SIVEXTRO® Healthcare Professional Site. Merck & Co., Inc.
• Moran, G. J., Fang, E., Corey, G. R., Das, A. F., De Anda, C., & Prokocimer, P. (2014). Tedizolid for 6 days versus linezolid for 10 days for treating acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Infectious Diseases, 14(8), 696–705.
• Flanagan, S., Minassian, S. L., Morris, D., et al. (2014). Pharmacokinetics of tedizolid in subjects with normal and impaired renal function. Antimicrobial Agents and Chemotherapy, 58(11), 6479–6485.